• Ceftazidime Workflows for Gram-Negative Research

  2026-09-09

  Ceftazidime supports practical susceptibility, time-kill, and resistance-transmission workflows centered on Gram-negative organisms, especially Pseudomonas aeruginosa. This guide connects assay design with plasmid-aware surveillance so researchers can distinguish antimicrobial phenotype from the genetic routes that sustain resistance.

• nor-NOHA Acetate for Arginase Assays

  2026-09-09

  nor-NOHA acetate provides a reversible way to test how arginine allocation influences tumor phenotypes, nitric oxide biology, and vascular readouts. Its strongest use is as a mechanistic comparator: pair arginase activity measurements with proliferation, apoptosis, invasion, or immune-cell assays rather than treating one endpoint as proof of pathway engagement.

• QX77 Molecular Chaperone Activator Guide

  2026-09-08

  QX77 is a molecular chaperone activator for chaperone-mediated autophagy research and stem cell biology research. Product information associates it with LAMP2A and Rab11 upregulation, ES cell self-renewal inhibition, and differentiation, while current BPD evidence provides related autophagy context rather than direct QX77 validation.

• Cyclo (-RGDfC): From Target Biology to Assay Design

  2026-09-08

  Cyclo (-RGDfC) is a cyclic RGD peptide for investigating integrin-mediated cell adhesion, tumor targeting, and angiogenesis. This article connects its αvβ3-binding biology with practical assay controls and lessons from canine osteosarcoma viability research.

• 2-NBDG: From Uptake Signal to Metabolic Insight

  2026-09-07

  2-NBDG enables fluorescent measurement of cellular glucose uptake, but its greatest value comes from connecting transport kinetics with metabolic mechanism. This guide explains how to interpret 2-NBDG data using the ERK/PKM2 arsenic-hepatocyte study as a model for rigorous glucose metabolism assays.

• Gemcitabine Assays for DNA Damage and Apoptosis

  2026-09-07

  Build reproducible Gemcitabine workflows that connect replication stress with checkpoint activation, apoptosis, and cancer-cell response. The guide combines dose-and-pulse design with gastric cancer stem-cell biology from the TAK1–YAP reference study, while clearly separating evidence from practical assay recommendations.

• Cyclic di-GMP and Biofilm Antibiotic Persistence

  2026-09-05

  The 2024 eLife study identifies cyclic di-GMP as a small-molecule antitoxin that restrains the genotoxic toxin HipH during early biofilm development. By linking adhesion-stage signaling to DNA double-strand breaks, genome instability, and persister formation, the work refines current models of biofilm resilience and suggests more precise designs for persistence research.

• ASB3-Mediated MAVS Degradation in Antiviral Immunity

  2026-09-04

  The 2024 Cell Death & Differentiation study identifies ASB3 as an inducible E3 ligase that suppresses antiviral innate immunity by promoting K48-linked ubiquitination and proteasomal degradation of MAVS. Genetic, biochemical, virological, and animal experiments connect this mechanism to reduced TBK1–IRF3 signaling, impaired type I interferon production, and increased susceptibility to influenza infection.

• Phosbind Biotin for Protein Phosphorylation Analysis

  2026-09-04

  Phosbind Biotin enables sequence-independent Western Blot detection of phosphorylated proteins without relying on phospho-specific antibodies. Its biotin–streptavidin-HRP workflow is particularly useful for comparing phosphorylation changes in plant drought-response models and signal transduction pathway research.

• Biomimetic CaCO3 Nanoparticles for GBM Sono-Immunotherapy

  2026-09-03

  Zhao et al. developed cRGD-modified cancer-cell-membrane-coated calcium carbonate nanoparticles to deliver IL-12 mRNA to glioblastoma and combine ultrasound-induced necroptosis with immune stimulation. The study offers a mechanistic framework for integrating blood–brain barrier navigation, localized mRNA expression, and immunogenic tumor-cell destruction, while also highlighting the need for rigorous delivery and expression controls.

• SNAI1–PIK3R2/p-EphA2 Axis in Thymic Tumors

  2026-09-03

  This 2024 study identifies SNAI1 as a transcriptional hub that promotes epithelial–mesenchymal transition and sustains cancer stem cell-like traits in thymic epithelial tumors through the PIK3R2/p-EphA2 axis. Integrated transcriptomic, epigenomic, single-cell, phosphoproteomic, and functional assays connect tumor-cell plasticity with macrophage-state changes, supporting SNAI1 as a mechanistically grounded therapeutic research target.

• Acifran: From Cryo-EM Structure to Assay Design

  2026-09-02

  Acifran is a structurally informative agonist for HCAR2/GPR109A and HCAR3/GPR109B research. This guide connects cryo-EM evidence with practical assay design, helping researchers distinguish receptor engagement, pathway activity, and apparent selectivity in lipid metabolism studies.

• QSHXO, Autophagy, and Ferroptosis in MASLD

  2026-09-02

  A 2026 World Journal of Hepatology study identifies coordinated autophagy activation and ferroptosis inhibition as a mechanistic basis for Qushi Huoxue ointment activity in a mouse model of metabolic associated steatotic liver disease. Its multi-method design links lipid and inflammatory improvement with changes in autophagy markers, Nrf2 signaling, iron deposition, and mitochondrial ultrastructure, while also highlighting important limits of model-based interpretation.

• SIS3: Precision Control of Smad3 in Translational Research

  2026-09-01

  SIS3 is a selective Smad3 inhibitor that enables researchers to separate Smad3-dependent TGF-β signaling from broader pathway effects. This thought-leadership guide connects its mechanism to fibrosis research, renal disease models, and osteoarthritis evidence, while outlining practical strategies for rigorous translational study design.

• EGCG Nanoparticles Enhance FLASH Radiotherapy

  2026-09-01

  Xu et al. developed functionalized, self-assembled EGCG nanoparticles (BENPs) to increase ROS generation, DNA damage, and tumor-cell killing during FLASH radiotherapy. In a 4T1 breast tumor model, the combination also stimulated antitumor immune features, although further work is needed to establish pharmacokinetics, optimal dosing, and clinical transferability.

7332 records 1/489 page Next 12345 下5页 Last page